Bioassay
Bioassay GmbH is a bioanalytical services company specializing in the development, validation, and routine testing of biologics and drug products. They support the pharmaceutical, chemical, and cosmetic industries with GMP and GLP certified assays, including potency, safety, physico-chemical analysis, and veterinary products. Their mission is to provide high-quality, regulatory-compliant bioanalytical testing solutions to support drug development and market approval.
Industries
Nr. of Employees
small (1-50)
Bioassay
Heidelberg, Baden-Württemberg, Germany
Patents
Products
Rituximab
Complement-dependent cytotoxicity (CDC) potency assay for Rituximab using Ramos cells and Alamar Blue fluorescence.
Rituximab Binding Assay (FACS) using Raji cells
Flow cytometry-based binding assay for Rituximab characterization and potency estimation utilizing Raji cells.
Rituximab Assay
Potency and characterization assays for Rituximab.
Rituximab (ADCC) Assay
Antibody-Dependent Cellular Cytotoxicity (ADCC) functional bioassay services for Rituximab.
OECD 442E
U-SENS cell line activation test for skin sensitization testing.
OECD 442E U937 Cell Line Activation Test (U-SENS™)
U-SENS cell line activation test for skin sensitization testing.
Rituximab
Complement-dependent cytotoxicity (CDC) potency assay for Rituximab using Ramos cells and Alamar Blue fluorescence.
Rituximab Binding Assay (FACS) using Raji cells
Flow cytometry-based binding assay for Rituximab characterization and potency estimation utilizing Raji cells.
Rituximab Assay
Potency and characterization assays for Rituximab.
Rituximab (ADCC) Assay
Antibody-Dependent Cellular Cytotoxicity (ADCC) functional bioassay services for Rituximab.
OECD 442E
U-SENS cell line activation test for skin sensitization testing.
OECD 442E U937 Cell Line Activation Test (U-SENS™)
U-SENS cell line activation test for skin sensitization testing.
Services
Contract development and validation of bioassays to measure potency and bioactivity for biologics, proteins, vaccines and APIs; includes method design, optimization, and qualification under GMP/GLP standards.
In vitro and in vivo GLP safety studies including toxicity, skin sensitization and immunotoxicity to support preclinical development and regulatory submissions.
Routine GMP potency testing and batch release support for biologics and veterinary biologics performed under GMP control to meet regulatory market release requirements.
Qualitative and quantitative physico-chemical testing using HPLC and related analytical techniques under GMP and non-GMP conditions.
Development, validation and GMP routine potency testing for veterinary vaccines, hormones and antibodies, plus immunotoxicity and safety evaluations tailored for animal health products.
Contract development and validation of bioassays to measure potency and bioactivity for biologics, proteins, vaccines and APIs; includes method design, optimization, and qualification under GMP/GLP standards.
In vitro and in vivo GLP safety studies including toxicity, skin sensitization and immunotoxicity to support preclinical development and regulatory submissions.
Routine GMP potency testing and batch release support for biologics and veterinary biologics performed under GMP control to meet regulatory market release requirements.
Qualitative and quantitative physico-chemical testing using HPLC and related analytical techniques under GMP and non-GMP conditions.
Development, validation and GMP routine potency testing for veterinary vaccines, hormones and antibodies, plus immunotoxicity and safety evaluations tailored for animal health products.
Expertise Areas
- Assay development and validation
- Bioanalytical contract research
- Potency and lot release testing
- GLP and GMP compliance for bioanalysis
Key Technologies
- Cell-based bioassays
- Reporter gene assays
- Primary cell assays
- High-performance liquid chromatography (HPLC)
News & Updates
Bioassay GmbH has obtained a veterinary GMP license according to Art. 88 of Regulation (EU) 2019/6.
Reaction Biology has acquired Bioassay GmbH, expanding its capabilities in large molecule drug discovery and development services.
Bioassay GmbH has obtained a veterinary GMP license according to Art. 88 of Regulation (EU) 2019/6.
Reaction Biology has acquired Bioassay GmbH, expanding its capabilities in large molecule drug discovery and development services.